Clinical trials: sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Lead sponsor (exact) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Has posted results yes
Biliary Atresia
Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia
The Children Liver Disease Research and Education Network (ChiLDREN) is conducting a clinical trial to determine the feasibility, acceptability, tolerability and safety profile of IVIG treatment administered to infants after…
- Trial name
- PRIME (NCT01854827)
- Testing
- Intravenous immunoglobulin (IVIG)
- Where
- 7 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Glomerulosclerosis, Focal
Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)
The FSGS Clinical Trial is a multi-center, prospective, controlled, open label randomized trial designed to determine if treatment with mycophenolate mofetil (MMF) in conjunction with pulse steroids is superior to treatment with…
- Trial name
- NCT00135811
- Testing
- Cyclosporin, Mycophenolate mofetil and Dexamethasone
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Cancer
Diabetes Prevention Program Outcomes Study
The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired…
- Conditions
- Diabetes Mellitus, Cancer, CVD
- Trial name
- DPPOS (NCT00038727)
- Testing
- DPPOS Group Lifestyle, Metformin, DPPOS Boost Lifestyle
- Where
- United States
- Volunteers
- 2,779 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Vitamin E Dosing Study
This is a multicenter, randomized, double masked, placebo-controlled, parallel treatment groups dosing trial of Vitamin E in adult nonalcoholic fatty liver disease (NAFLD).
- Trial name
- VEDS (NCT04801849)
- Testing
- Vitamin E
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1
STOP-T1D Low-Dose (ATG)
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
- Trial name
- TN28 (NCT04291703)
- Testing
- Antithymocyte Globulin
- Where
- 22 sites in United States, Australia
- Volunteers
- 2 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Bladder Diseases, Interstitial Cystitis
Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS)
This is a randomized clinical trial study to test the efficacy and safety of amitriptyline in the treatment of patients newly diagnosed with painful bladder syndrome (PBS).
- Trial name
- IC01 (NCT00124306)
- Testing
- Amitriptyline
- Where
- 10 sites in United States, Canada
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
The purpose of this study is to determine whether pregabalin is an effective treatment for Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
- Trial name
- CPCRN RCT#2 (NCT00371033)
- Testing
- Pregabalin
- Where
- 11 sites in United States, Canada
- Volunteers
- 324 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy Volunteers
Food Intake Response to Short-Term Modifications of Metabolism in Humans
One reason people gain weight is eating more calories from food than what they need for energy over 24 hours. Metabolism is the amount of energy a person uses over 24 hours.
- Trial name
- NCT02939404
- Testing
- Cold exposure, Normal temperature, Fixed diet
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type I Diabetes
A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
The trial is a placebo-controlled, double-blinded within cohorts, randomized, multiple ascending dose trial with a sequential trial design.
- Trial name
- TOPPLE T1D (NCT04279613)
- Testing
- NNC0361-0041
- Where
- 16 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Severe Insulin Resistance
Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance
Study Description: Patients with mutations of the insulin receptor have diabetes that is challenging to control with conventional therapies, leading to early morbidity and mortality.
- Trial name
- NCT00085982
- Testing
- Metreleptin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End Stage Renal Disease, Chronic Pain
HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis
HOPE is a randomized clinical trial that will evaluate approaches to reducing pain and opioid use among patients with chronic pain who are receiving maintenance hemodialysis for end-stage renal disease.
- Conditions
- End Stage Renal Disease, Chronic Pain, Opioid Dependence
- Trial name
- HOPE (NCT04571619)
- Testing
- Pain Coping Skills Training (PCST), Buprenorphine
- Where
- 16 sites in United States
- Volunteers
- 643 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy Volunteers
Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate
Background: Changes in how a person's body burns energy or calories can affect their weight over time. The lowest level of energy the body needs to function is called basal metabolic rate.
- Trial name
- NCT01950520
- Testing
- Propranolol, Pindolol, Dantrolene
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Leiomyoma
Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914
This study will evaluate whether the experimental drug ulipristal acetate can shrink uterine fibroids in pre-menopausal women.
- Trial name
- NCT00290251
- Testing
- ulipristal acetate 20 mg, ulipristal acetate 10 mg
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Cortisol Resistance, Negative Feedback
Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men
This study proposes to examine multiple aspects of the hypothalamic-pituitary-adrenal axis in younger endurance trained and sedentary men, and in older sedentary men.
- Conditions
- Cortisol Resistance, Negative Feedback, ACTH, Mineralcorticoid
- Trial name
- NCT01294319
- Testing
- Mifepristone, Spironolactone, Combined
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Abnormal Glucose Tolerance, Type 1 Diabetes
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1
The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial. All subjects will receive close monitoring for development of AGT or T1DM.
- Trial name
- NCT01773707
- Testing
- CTLA4-Ig (Abatacept)
- Where
- 17 sites in United States, Canada
- Volunteers
- 212 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type1 Diabetes Mellitus
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for progression of T1D.
- Trial name
- TN-22 (NCT03428945)
- Testing
- Hydroxychloroquine
- Where
- 51 sites in United States, Australia and 4 more
- Volunteers
- 273 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 2 Diabetes
Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes
Background: The pill metformin treats diabetes. But it does not work for all youth, especially African-Americans. The injectable Liraglutide treats type 2 diabetes in adults.
- Trial name
- NCT02960659
- Testing
- Liraglutide, Metformin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Obesity, Healthy Volunteers
Brain Dopamine Function in Human Obesity
Background: Dopamine is a natural chemical in the brain that may influence eating behavior and physical activity. Researchers want to measure the brain s dopamine activity and understand how it differs in people with obesity.
- Conditions
- Obesity, Healthy Volunteers, Overweight
- Trial name
- NCT03648892
- Testing
- [c11] raclopride, [18F]fallypride
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis B
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B
This clinical trial compares the efficacy of peginterferon plus tenofovir for 24 weeks followed by monotherapy with tenofovir for a further 3.5 years to the efficacy of tenofovir alone given for 4 years in patients with chronic…
- Trial name
- HBRN (NCT01369212)
- Testing
- Tenofovir, Peginterferon-alfa 2a and tenofovir
- Where
- 21 sites in United States, Canada
- Volunteers
- 201 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes
Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)
Background: Metformin is a pill youth with type 2 diabetes take. It can cause side effects like diarrhea and upset stomach. Researchers want to see if a fiber supplement can help decrease these side effects.
- Trial name
- NCT04209075
- Testing
- Biomebliss, Metformin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)